Daily Roundup

CSL expands rare disease pipeline with Alentis partnership

CSL Ltd. has inked an exclusive agreement with Alentis Therapeutics to co-develop and co-promote lixudebart, a potential first-in-class treatment for rare kidney and liver diseases. The partnership marks a significant move into immunology-focused rare disease treatment, with CSL committing an upfront payment of US$355 million and potentially another US$1.2 billion in commercial milestones down the line.

Lixudebart is currently being evaluated in a Phase 2 trial for ANCA-associated vasculitis and rapidly progressive glomerulonephritis, with plans to advance the candidate into additional indications including focal segmental glomerulosclerosis and primary sclerosing cholangitis. CSL will fund the completion of ongoing and planned trials, positioning itself to lead development across multiple rare kidney and liver conditions.

Aroa Biosurgery's wound care product shows real clinical promise

In biotech news, Aroa Biosurgery Ltd. released encouraging results from a randomized controlled trial for Symphony, its diabetic foot ulcer treatment. The trial, which involved 143 patients across 10 US sites, found that adding Symphony to standard care significantly improved healing outcomes. Fifty-five percent of patients using Symphony achieved complete wound closure within 12 weeks, compared to just 35% in the standard care group. Even more impressive, the mean time to complete healing dropped by 7.8 days—from 73.2 days down to 65.4 days—suggesting the product could meaningfully speed recovery for diabetic patients.

Dimerix hits four-year milestone in FSGS program

Dimerix Limited announced that the first patient has successfully completed four years in its DMX-200 clinical development program for focal segmental glomerulosclerosis. The achievement spans both the two-year ACTION3 Phase 3 trial and a subsequent two-year Open Label Extension study. With over 90% of eligible patients choosing to continue into the extension phase, the strong participation rate underscores patient and investigator confidence in the treatment. The company is also planning to establish a post-trial access program pending ethics approval, ensuring continued access for patients beyond the formal trial.

Gold miners report solid quarterly production

On the commodities side, gold producers delivered mixed results. Capricorn Metals Ltd. produced 31,218 ounces of gold in Q1, staying on track with its fiscal 2027 guidance of 137,000 to 147,000 ounces. The company successfully completed its Karlawinda Expansion Project on schedule and within budget, boosting processing capacity to 6.5 million tonnes per annum and expected annual production to 150,000 ounces. Development activities at the Mt Gibson Gold Project have also progressed, with federal approval secured.

Meanwhile, Predictive Discovery Ltd. poured 52,866 ounces of gold during the September quarter, with its Kiniero operation running above nameplate capacity at 88.3% recovery rates. The company ended the period with US$405 million in cash and bullion. Production at Nampala was hampered by ore access challenges as pit cutback activities continued, though Kiniero's stable operations more than compensated.

Predictive Discovery eyes significant exploration upside

Predictive Discovery also reported high-grade gold drilling results from its Kiniéro Gold Project in Guinea, with notable intercepts including 28.35 metres at 5.87 grams per tonne of gold. Structural analysis suggests the veins form part of a larger, interconnected system with room for expansion. The company plans to ramp up exploration efforts in 2027 with approximately 1,800 drill holes targeting 140,000 metres, aiming to unlock additional mineral resources and extend mine life.